
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes”, Epidemiology, 2020.
, “The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study”, Drug Saf, 2019.
, “Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 904-912, 2018.
, “Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism”, Am J Epidemiol, 2019.
, “Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study”, Bmj, vol. 362, p. k2693, 2018.
, “Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes”, Diabetes Care, vol. 42, pp. e150-e152, 2019.
, “SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study”, Pharmacoepidemiol Drug Saf, 2021.
, “Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events”, Diabetes Care, vol. 40, pp. 1506-1513, 2017.
, “Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 246-253, 2018.
, “Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes”, Diabet Med, 2020.
, “Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes”, Diabetes Care, 2019.
, “Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 360, p. k872, 2018.
, “Defining Clinically-Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials”, Clin Pharmacol Ther, 2021.
, , ,